LXEOLexeo TherapeuticsRunning, no new patients
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Friedreich Ataxia · Cardiomyopathy, Secondary
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4
3 insiders sold shares within a month
Since Aug 18, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 1/2
- Patients
- 8 (final count)
- Started
- Aug 24, 2022
- Main results expected
- Sep 2029
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)
Measured over: Change from baseline to end of year 5 post dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4, since 2026-08-18, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05445323 · record last updated 2025-12-23 · checked 2026-11-09 15:42 UTC